E-ISSN 2231-3206 | ISSN 2320-4672
 
2024, Vol: 14, Issue: 10
14 / 10Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles
Required files to be uploaded

Authorship Declaration

Original Research
Online Published: 10 Apr 2024
 


A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital

Shukrath Chandrappa, Shabari Shetty, Arun Thungani Narayana, Kavitha Rajarathna.


Abstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic disorder with progressive pancreatic β-cell dysfunction and insulin resistance. Hyperglycemia associated with uncontrolled T2DM leads to various diabetes-related complications. Although metformin is the most preferred first-line drug, 5–10% of patients per year subsequently fail to achieve target HbA1c levels, subsequently requiring combination therapy. While efficacy and cost favor the use of sulfonylureas, hypoglycemic episodes limit its use. Newer generation sulfonylureas such as glimepiride and gliclazide are presumed to have lower incidence of hypoglycemia.

Aims and Objectives: The aim of the study was to assess the efficacy and safety of glimepiride versus gliclazide as an add-on to metformin in T2DM.

Materials and Methods: A total of 60 patients with T2DM (HbA1c 7.0–10.0%, on metformin monotherapy) were recruited and randomized into two groups of 30 cases each. Group A received glimepiride 2 mg as add-on to metformin 1500 mg and Group B received gliclazide 80 mg as add-on to metformin 1500 mg. HbA1c, lipid profile, body mass index, and total blood count were assessed at baseline and at the end 12 weeks of treatment. Fasting blood sugar (FBS) and post prandial blood sugar (PPBS) were assessed at the end of 4, 8, and 12 weeks and adverse events were assessed throughout the study period.

Results: There was a significant decrease in HbA1c, FBS, and PPBS scores from baseline to the end of 12 weeks in both groups (P < 0.001), but the difference was not statistically significant between the two groups (P > 0.05). A significant decrease in lipid levels was observed in both groups except for high-density lipoprotein, low-density lipoprotein in the metformin + gliclazide group. The treatment was well tolerated in both groups, with the most common adverse events being nausea, diarrhea, and epigastric pain.

Conclusion: Glimepiride and gliclazide are both equally effective as an add-on to metformin in improving glycaemic indices and are well tolerated in the management of uncontrolled T2DM.

Key words: Glimepiride; Gliclazide; Combination Drug Therapy; Metformin; Diabetes Mellitus; Glycaemic Indices


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Shukrath Chandrappa
Articles by Shabari Shetty
Articles by Arun Thungani Narayana
Articles by Kavitha Rajarathna
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Chandrappa S, Shetty S, Narayana AT, Rajarathna K. A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2024; 14(9): 1824-1830. doi:10.5455/njppp.2024.14.03142202430032024

Web Style

Chandrappa S, Shetty S, Narayana AT, Rajarathna K. A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital. https://www.njppp.com/?mno=195552 [Access: October 03, 2024]. doi:10.5455/njppp.2024.14.03142202430032024

AMA (American Medical Association) Style

Chandrappa S, Shetty S, Narayana AT, Rajarathna K. A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2024; 14(9): 1824-1830. doi:10.5455/njppp.2024.14.03142202430032024


Vancouver/ICMJE Style

Chandrappa S, Shetty S, Narayana AT, Rajarathna K. A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital. Natl J Physiol Pharm Pharmacol. (2024), [cited October 03, 2024]; 14(9): 1824-1830. doi:10.5455/njppp.2024.14.03142202430032024


Harvard Style

Chandrappa, S., Shetty, . S., Narayana, . A. T. & Rajarathna, . K. (2024) A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital. Natl J Physiol Pharm Pharmacol, 14 (9), 1824-1830. doi:10.5455/njppp.2024.14.03142202430032024


Turabian Style

Chandrappa, Shukrath, Shabari Shetty, Arun Thungani Narayana, and Kavitha Rajarathna. 2024. A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 14 (9), 1824-1830. doi:10.5455/njppp.2024.14.03142202430032024


Chicago Style

Chandrappa, Shukrath, Shabari Shetty, Arun Thungani Narayana, and Kavitha Rajarathna. "A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 14 (2024), 1824-1830. doi:10.5455/njppp.2024.14.03142202430032024


MLA (The Modern Language Association) Style

Chandrappa, Shukrath, Shabari Shetty, Arun Thungani Narayana, and Kavitha Rajarathna. "A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 14.9 (2024), 1824-1830. Print. doi:10.5455/njppp.2024.14.03142202430032024


APA (American Psychological Association) Style

Chandrappa, S., Shetty, . S., Narayana, . A. T. & Rajarathna, . K. (2024) A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 14 (9), 1824-1830. doi:10.5455/njppp.2024.14.03142202430032024




Most Viewed Articles
Most Accessed Articles

  • Applications of computer science in Pharmacy: An overview
    Shivraj Popat Jadhav, Komal Nikam, Anand Gandhi, Kishor Salunkhe, Narendra Shinde.
    Natl J Physiol Pharm Pharmacol. 2012; 2(1): 1-9
    » Abstract

  • How to calculate sample size in animal studies?
    Hitesh Shah
    Natl J Physiol Pharm Pharmacol. 2011; 1(1): 35-39
    » Abstract

  • Chlorhexidine:The gold standard in chemical plaque control [English]
    Setu mathur, Tanu mathur,Rahul shrivastava, Rohit khatri
    Natl J Physiol Pharm Pharmacol. 2011; 1(2): 45-50
    » Abstract

  • Assessment of Nutritional Status of Pregnant Women Attending the City Tebessa PMI (Algeria) [English]
    Taleb Salima, Kaibi Mounira, Deghboudj Nadjia
    Natl J Physiol Pharm Pharmacol. 2011; 1(2): 97-105
    » Abstract

  • Difference in pulmonary function test among the athletic and sedentary population
    ShobhaRani Vedala, Niranjan Paul, Abhay B Mane
    Natl J Physiol Pharm Pharmacol. 2013; 3(2): 118-123
    » Abstract » doi: 10.5455/njppp.2013.3.109-114

    •
    Most Downloaded
    Top Downloaded Articles

  • How to calculate sample size in animal studies?
    Hitesh Shah
    Natl J Physiol Pharm Pharmacol. 2011; 1(1): 35-39
    » Abstract

  • Applications of computer science in Pharmacy: An overview
    Shivraj Popat Jadhav, Komal Nikam, Anand Gandhi, Kishor Salunkhe, Narendra Shinde.
    Natl J Physiol Pharm Pharmacol. 2012; 2(1): 1-9
    » Abstract

  • Evaluation of potential drug-drug interaction in indoor patients of pediatric department of tertiary care hospital
    Simran Patel, Mayur Chaudhari, Nrupal Patel
    Natl J Physiol Pharm Pharmacol. 2019; 9(10): 1012-1016
    » Abstract » doi: 10.5455/njppp.2019.9.0725209072019

  • Chlorhexidine:The gold standard in chemical plaque control [English]
    Setu mathur, Tanu mathur,Rahul shrivastava, Rohit khatri
    Natl J Physiol Pharm Pharmacol. 2011; 1(2): 45-50
    » Abstract

  • Analyzing Pharmaceutical Industry [English]
    Veselin Tima Dickov, Dragan Mitrovic, Boris Milan Kuzman
    Natl J Physiol Pharm Pharmacol. 2011; 1(1): 1-8
    » Abstract » doi: 10.5455/njppp.2011.1.1-8

    •
    Most Cited Articles
    Most Cited Articles

    About National Journal of Physiology, Pharmacy and Pharmacology

      National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal.  The journal is having open access polic ... Read more.



    For best results, please use Internet Explorer or Google Chrome.

    Contact Information

    Eldaghayes Publisher

    www.eldagpublisher.com 

     
    All correspondence should be addressed to:
    Prof. Ibrahim Eldaghayes
    Editor-in-Chief
    National Journal of Physiology, Pharmacy and Pharmacology
    Email: ibrahim.eldaghayes@vetmed.edu.ly
    POLICIES & JOURNAL LINKS
    Author Login
    Reviewer Login
    About Publisher
    Advertising Policy
    Author's Rights and Obligations
    Conflict of Interest Policy
    Copyright Information
    Digital Archiving & Preservation Policies
    Editorial Policies
    Peer Review Policy
    Editorial & Peer Review Process
    License Information
    Open Access Policy
    Plagiarism Policy
    Privacy Policy
    Protection of Research Participants (Statement On Human And Animal Rights)
    Publication Ethics and Publication Malpractice Statement
    Corrections, Retractions & Expressions of Concern
    Self-Archiving Policies
    Statement of Informed Consent
    Terms of Use